Dr. Reddys Laboratories announced today that it has launched Olanzapine Tablets (2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg), a bioequivalent generic version of ZYPREXA Tablets in the US market on April 23, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddys ANDA for Olanzapine Tablets.
Dr. Reddys Olanzapine Tablets in 20 mg had been awarded a 180-day period of marketing exclusivity in the U.S. on October 26, 2011 which was commercialized through a commercial, manufacture and supply agreement with Teva Pharmaceutical Industries Ltd.
The ZYPREXA Tablets brand and generic had combined U.S. sales of approximately $3.28 billion for the most recent twelve months ending January 2012 according to IMS Health.
Dr. Reddys Olanzapine Tablets in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg strengths are available in 30 and 500 count bottles.
India Infoline Research Team / 08:49, Aug 21, 2014
The outlook is a flat open. Global indices are up. The minutes from the Federal Reserve's July meeting indicate that the Fed is in no hurry to raise interest rates. The Dow added 0.35% while S&P was up 0.25%. Nasdaq ended marginally lower. Asian indices are mixed with Nikkei up almost a percent while Hong Kong's Hang Seng index is lower. South Korea's Kospi index and China's Shanghai index are also in the red.